Maternal diabetes affects specific extracellular matrix components during placentation.
During embryo implantation, invasive trophoblast cells mediate embryo invasion into the decidualized stroma, forming a rich network of lacunae that connect the embryonic tissues to the maternal blood vessels. Placentation is probably guided by the composition and organization of the endometrial extracellular matrix. Certain pathological conditions that occur during pregnancy, including diabetes, have been linked to abnormal placental morphology and consequent fetal morbidity. We used immunoperoxidase techniques to identify members of the collagen, proteoglycan and glycoprotein families in the various compartments of the rat placenta and to determine whether experimentally induced diabetes affects placental morphology and alters the distribution of these molecules during pregnancy. Single injections of alloxan (40 mg kg(-1) i.v.) were used to induce diabetes on day 2 of pregnancy in Wistar rats. Placentas were collected on days 14, 17, and 20. Type I and III collagen, as well as the proteoglycans decorin and biglycan, were found to be distributed throughout the placentas of control and diabetic rats. In both groups, laminin expression decreased at the end of pregnancy. In contrast, fibronectin was detected in the labyrinth region of diabetic rats at all gestational stages studied, whereas it was detected only at term pregnancy in the placentas of control rats. These results show for the first time that some extracellular matrix molecules are modulated during placental development. However, as diabetic rats presented increased fibronectin deposition exclusively in the labyrinth region, we speculate that diabetes alters the microenvironment at the maternal-fetal interface, leading to developmental abnormalities in the offspring.
Giachini
F R C
FR
Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil.
Carriel
V
V
Capelo
L P
LP
Tostes
R C
RC
Carvalho
M H
MH
Fortes
Z B
ZB
Zorn
T M
TM
San Martin
S
S
D000818:Animals; D058578:Biglycan; D024042:Collagen Type I / Q000032:analysis; D024061:Collagen Type III / Q000032:analysis; D058575:Decorin; D003921:Diabetes Mellitus, Experimental / Q000473:pathology*; D016640:Diabetes, Gestational / Q000473:pathology*; D004717:Endometrium / Q000737:chemistry; D016326:Extracellular Matrix Proteins / Q000032:analysis*; D005260:Female; D005353:Fibronectins / Q000032:analysis; D007124:Immunoenzyme Techniques; D007797:Laminin / Q000032:analysis; D010920:Placenta / Q000737:chemistry; D010929:Placentation; D011247:Pregnancy; D011509:Proteoglycans / Q000032:analysis; D051381:Rats; D017208:Rats, Wistar
C546886:Bgn protein, rat; D058578:Biglycan; D024042:Collagen Type I; D024061:Collagen Type III; C546880:Dcn protein, rat; D058575:Decorin; D016326:Extracellular Matrix Proteins; D005353:Fibronectins; D007797:Laminin; D011509:Proteoglycans